Abstract:Assessment of minimal residual disease (MRD) is becoming a standard diagnostic tool for curable hematological malignancies such as chronic and acute myeloid leukemia. Multiple myeloma (MM) remains an incurable disease, as a major portion of patients even in complete response eventually relapse, suggesting that residual disease remains. Over the past decade, the treatment landscape of MM has radically changed with the introduction of new effective drugs and the availability of immunotherapy, including targeted antibodies and adoptive cell therapy. Therefore, conventional serological and morphological techniques have become suboptimal for the evaluation of depth of response. Recently, the International Myeloma Working Group (IMWG) introduced the definition of MRD negativity as the absence of clonal Plasma cells (PC) with a minimum sensitivity of <10 −5 either by next-generation sequencing (NGS) using the LymphoSIGHT platform (Sequenta/Adaptative) or by next-generation flow cytometry (NGF) using EuroFlow approaches as the reference methods. While the definition of the LymphoSIGHT platform (Sequenta/Adaptive) as the standard method derives from its large use and validation in clinical studies on the prognostic value of NGS-based MRD, other commercially available options exist. Recently, the LymphoTrack assay has been evaluated in MM, demonstrating a sensitivity level of 10 −5 , hence qualifying as an alternative effective tool for MRD monitoring in MM. Here, we will review state-of-the-art methods for MRD assessment by NGS. We will summarize how MRD testing supports clinical trials as a useful tool in dynamic risk-adapted therapy. Finally, we will also discuss future promise and challenges of NGS-based MRD determination for clinical decision-making. In addition, we will present our real-life single-center experience with the commercially available NGS strategy LymphoTrack-MiSeq. Even with the limitation of a limited number of patients, our results confirm the LymphoTrack-MiSeq platform as a cost-effective, readily available, and standardized workflow with a sensitivity of 10 −5 . Our real-life data also confirm that achieving MRD negativity is an important prognostic factor in MM.

MRD Assessment in Multiple Myeloma: Progress and Challenges

Multiple myeloma, immunotherapy and minimal residual disease

Minimal Residual Disease Assessment in Multiple Myeloma Patients: Minimal Disease With Maximal Implications

Minimal Residual Disease in Multiple Myeloma: Past, Present, and Future

Measurable Residual Disease Assessment in Multiple Myeloma: How Deep Is Enough?

Role of minimal residual disease assessment in multiple myeloma

Minimal residual disease detection by next-generation sequencing in multiple myeloma: Promise and challenges for response-adapted therapy

Drug resistance and minimal residual disease in multiple myeloma

Modern approaches to assessment of minimal residual disease in multiple myeloma (plasma cell myeloma) cases

Minimal Residual Disease-Adapted Therapy in Multiple Myeloma: Current Evidence and Opinions

Clinical Significance and Detection Techniques of Minimal Residual Disease in Multiple Myeloma——Review

MRD in multiple myeloma: does CR really matter?

Clinical value of measurable residual disease testing for assessing depth, duration, and direction of response in multiple myeloma

Minimal Residual Disease in Multiple Myeloma: Current Status

Research Progress of Methods of Minimal Residual Disease Detection in Multiple Myeloma

Measurable Residual Disease and Decision-Making in Multiple Myeloma

Measurable Residual Disease Testing in Multiple Myeloma Following T-Cell Redirecting Therapies

Dynamics of minimal residual disease and its clinical implications in multiple myeloma: A retrospective real-life analysis

Implementation of an AI-based MRD evaluation and prediction model for multiple myeloma

Multiparametric Flow Cytometry for MRD Monitoring in Hematologic Malignancies: Clinical Applications and New Challenges

Minimal residual disease in multiple myeloma: Benefits of flow cytometry